系统性念珠菌病

Tsay SV, Mu Y, Williams S, et al. Burden of candidemia in the United States, 2017. Clin Infect Dis. 2020 Dec 3;71(9):e449-53.全文  摘要

Centers for Disease Control and Prevention. ​Candida auris: information for laboratorians and health professionals. Jul 2021 [internet publication].全文

Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016 Feb 15;62(4):e1-50.全文  摘要

Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016 Feb 15;62(4):e1-50.全文  摘要

1. Zhang AY, Shrum S, Williams S, et al. The changing epidemiology of candidemia in the United States: injection drug use as an increasingly common risk factor-active surveillance in selected sites, United States, 2014-2017. Clin Infect Dis. 2020 Oct 23;71(7):1732-7.全文  摘要

2. Pappas PG. Invasive candidiasis. Infect Dis Clin North Am. 2006 Sep;20(3):485-506. 摘要

3. Tsay SV, Mu Y, Williams S, et al. Burden of candidemia in the United States, 2017. Clin Infect Dis. 2020 Dec 3;71(9):e449-53.全文  摘要

4. Lamoth F, Lockhart SR, Berkow EL, et al. Changes in the epidemiological landscape of invasive candidiasis. J Antimicrob Chemother. 2018 Jan 1;73(suppl_1):i4-13.全文  摘要

5. Bongomin F, Gago S, Oladele RO, et al. Global and multi-national prevalence of fungal diseases-estimate precision. J Fungi (Basel). 2017 Oct 18;3(4):57.全文  摘要

6. Centers for Disease Control and Prevention​. Antibiotic resistance threats in the United States, 2019. Dec 2019 [internet publication].全文

7. World Health Organization. WHO fungal priority pathogens list to guide research, development and public health action. 2022 [internet publication].全文

8. Horn DL, Neofytos D, Anaissie EJ, et al. Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. Clin Infect Dis. 2009 Jun 15;48(12):1695-703. 摘要

9. Pfaller MA, Diekema DJ, Turnidge JD, et al. Twenty years of the SENTRY Antifungal Surveillance Program: results for candida species from 1997-2016. Open Forum Infect Dis. 2019 Mar;6(suppl 1):S79-94.全文  摘要

10. Colombo AL, Nucci M, Park BJ, et al. Epidemiology of candidemia in Brazil: a nationwide sentinel surveillance of candidemia in eleven medical centers. J Clin Microbiol. 2006 Aug;44(8):2816-23. 摘要

11. Chai YA, Wang Y, Khoo AL, et al. Predominance of Candida tropicalis bloodstream infections in a Singapore teaching hospital. Med Mycol. 2007 Aug;45(5):435-9. 摘要

12. Almirante B, Rodriguez D, Cuenca-Estrella M, et al. Epidemiology, risk factors, and prognosis of Candida parapsilosis bloodstream infections: case-control population-based surveillance study of patients in Barcelona, Spain, from 2002 to 2003. J Clin Microbiol. 2006 May;44(5):1681-5.全文  摘要

13. Diekema D, Arbefeville S, Boyken L, et al. The changing epidemiology of healthcare-associated candidemia over three decades. Diagn Microbiol Infect Dis. 2012 May;73(1):45-8. 摘要

14. Centers for Disease Control and Prevention. Tracking Candida auris.​ Feb 2023 [internet publication].全文

15. Kohlenberg A, Monnet DL, Plachouras D, et al. Increasing number of cases and outbreaks caused by Candida auris in the EU/EEA, 2020 to 2021. Euro Surveill. 2022 Nov;27(46):2200846.全文  摘要

16. Centers for Disease Control and Prevention. ​Candida auris: information for laboratorians and health professionals. Jul 2021 [internet publication].全文

17. Venditti M. Clinical aspects of invasive candidiasis: endocarditis and other localized infections. Drugs. 2009;69(suppl 1):39-43. 摘要

18. Ziakas PD, Kourbeti IS, Voulgarelis M, et al. Effectiveness of systemic antifungal prophylaxis in patients with neutropenia after chemotherapy: a meta-analysis of randomized controlled trials. Clin Ther. 2010 Dec;32(14):2316-36. 摘要

19. Wang J, Zhan P, Zhou R, et al. Prophylaxis with itraconazole is more effective than prophylaxis with fluconazole in neutropenic patients with hematological malignancies: a meta-analysis of randomized-controlled trials. Med Oncol. 2010 Dec;27(4):1082-8. 摘要

20. Tamura K, Drew R. Antifungal prophylaxis in adult hematopoietic stem cell transplant recipients. Drugs Today (Barc). 2008 Jul;44(7):515-30. 摘要

21. Wingard JR, Carter SL, Walsh TJ, et al; Blood and Marrow Transplant Clinical Trials Network. Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. Blood. 2010 Dec 9;116(24):5111-8. 摘要

22. Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016 Feb 15;62(4):e1-50.全文  摘要

23. Buetti N, Marschall J, Drees M, et al. Strategies to prevent central line-associated bloodstream infections in acute-care hospitals: 2022 Update. Infect Control Hosp Epidemiol. 2022 May;43(5):553-69.全文  摘要

24. Pacilli M, Kerins JL, Clegg WJ, et al. Regional emergence of Candida auris in Chicago and lessons learned from intensive follow-up at 1 ventilator-capable skilled nursing facility. Clin Infect Dis. 2020 Dec 31;71(11):e718-25.全文  摘要

25. ​National Institute for Health and Care Excellence. Sepsis: recognition, diagnosis and early management. Sep 2017 [internet publication].全文

26. Kollef M, Micek S, Hampton N, et al. Septic shock attributed to Candida infection: importance of empiric therapy and source control. Clin Infect Dis. 2012 Jun;54(12):1739-46. 摘要

27. Karageorgopoulos DE, Vouloumanou EK, Ntziora F, et al. β-D-glucan assay for the diagnosis of invasive fungal infections: a meta-analysis. Clin Infect Dis. 2011 Mar 15;52(6):750-70. 摘要

28. Persat F, Ranque S, Derouin F, et al. Contribution of the (1-->3)-beta-D-glucan assay for diagnosis of invasive fungal infections. J Clin Microbiol. 2008 Mar;46(3):1009-13.全文  摘要

29. Ostrosky-Zeichner L, Alexander BD, Kett DH, et al. Multicenter clinical evaluation of the (1-->3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis. 2005 Sep 1;41(5):654-9. 摘要

30. Onishi A, Sugiyama D, Kogata Y, et al. Diagnostic accuracy of serum 1,3-β-D-glucan for pneumocystis jiroveci pneumonia, invasive candidiasis, and invasive aspergillosis: systematic review and meta-analysis. J Clin Microbiol. 2012 Jan;50(1):7-15.全文  摘要

31. Mylonakis E, Clancy CJ, Ostrosky-Zeichner L, et al. T2 magnetic resonance assay for the rapid diagnosis of candidemia in whole blood: a clinical trial. Clin Infect Dis. 2015 Mar 15;60(6):892-9. 摘要

32. Clancy CJ, Nguyen MH. T2 magnetic resonance for the diagnosis of bloodstream infections: charting a path forward. J Antimicrob Chemother. 2018 Mar 1;73(suppl_4):iv2-iv5.全文  摘要

33. Nguyen MH, Wissel MC, Shields RK, et al. Performance of Candida real-time polymerase chain reaction, β-D-glucan assay, and blood cultures in the diagnosis of invasive candidiasis. Clin Infect Dis. 2012 May;54(9):1240-8. 摘要

34. US Food and Drug Administration. FDA authorizes new use of test, first to identify the emerging pathogen Candida auris. April 2018 [internet publication].全文

35. Kedzierska A, Kochan P, Pietrzyk A, et al. Current status of fungal cell wall components in the immunodiagnostics of invasive fungal infections in humans: galactomannan, mannan and (1-->3)-beta-D-glucan antigens. Eur J Clin Microbiol Infect Dis. 2007 Nov;26(11):755-66. 摘要

36. Marty FM, Lowry CM, Lempitski SJ, et al. Reactivity of (1-->3)-beta-D-glucan assay with commonly used intravenous antimicrobials. Antimicrob Agents Chemother. 2006 Oct;50(10):3450-3.全文  摘要

37. Garey KW, Rege M, Pai MP, et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis. 2006 Jul 1;43(1):25-31. 摘要

38. Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother. 2005 Sep;49(9):3640-5.全文  摘要

39. Patel GP, Simon D, Scheetz M, et al. The effect of time to antifungal therapy on mortality in Candidemia associated septic shock. Am J Ther. 2009 Nov-Dec;16(6):508-11. 摘要

40. Denning DW. Echinocandin antifungal drugs. Lancet. 2003 Oct 4;362(9390):1142-51. 摘要

41. Betts RF, Nucci M, Talwar D, et al; Caspofungin High-Dose Study Group. A Multicenter, double-blind trial of a high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasis. Clin Infect Dis. 2009 Jun 15;48(12):1676-84. 摘要

42. Gafter-Gvili A, Vidal L, Goldberg E, et al. Treatment of invasive candidal infections: systematic review and meta-analysis. Mayo Clin Proc. 2008 Sep;83(9):1011-21. 摘要

43. Andes DR, Safdar N, Baddley JW, et al. Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials. Clin Infect Dis. 2012 Apr;54(8):1110-22.全文  摘要

44. Kale-Pradhan PB, Morgan G, Wilhelm SM, et al. Comparative efficacy of echinocandins and nonechinocandins for the treatment of Candida parapsilosis Infections: a meta-analysis. Pharmacotherapy. 2010 Dec;30(12):1207-13. 摘要

45. Cleveland AA, Farley MM, Harrison LH, et al. Changes in incidence and antifungal drug resistance in candidemia: results from population-based laboratory surveillance in Atlanta and Baltimore, 2008-2011. Clin Infect Dis. 2012 Nov 15;55(10):1352-61.全文  摘要

46. Alexander BD, Johnson MD, Pfeiffer CD, et al. Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. Clin Infect Dis. 2013 Jun;56(12):1724-32.全文  摘要

47. Pappas PG, Rotstein CM, Betts RF, et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis. 2007 Oct 1;45(7):883-93. 摘要

48. Rex JH, Pappas PG, Karchmer AW, et al. National Institute of Allergy and Infectious Diseases Mycoses Study Group. A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin Infect Dis. 2003 May 15;36(10):1221-8. 摘要

49. Rex JH, Bennett JE, Sugar AM, et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. N Engl J Med. 1994 Nov 17;331(20):1325-30.全文  摘要

50. Reboli AC, Rotstein C, Pappas PG, et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med. 2007 Jun 14;356(24):2472-82.全文  摘要

51. Kullberg BJ, Sobel JD, Ruhnke M, et al. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet. 2005 Oct 22-28;366(9495):1435-42. 摘要

52. Tissot F, Agrawal S, Pagano L, et al. ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients. Haematologica. 2017 Mar;102(3):433-4.全文  摘要

53. Kullberg BJ, Arendrup MC. Invasive candidiasis. N Engl J Med. 2015 Oct 8;373(15):1445-56. 摘要

54. Riddell J 4th, Comer GM, Kauffman CA. Treatment of endogenous fungal endophthalmitis: focus on new antifungal agents. Clin Infect Dis. 2011 Mar 1;52(5):648-53. 摘要

55. Pachl J, Svoboda P, Jacobs F, et al. A randomized, blinded, multicenter trial of lipid-associated amphotericin B alone versus in combination with an antibody-based inhibitor of heat shock protein 90 in patients with invasive candidiasis. Clin Infect Dis. 2006;42:1404-1413. 摘要

56. Oliveira LVN, Wang R, Specht CA, et al. Vaccines for human fungal diseases: close but still a long way to go. NPJ Vaccines. 2021 Mar 3;6(1):33.全文  摘要

57. Thompson GR 3rd, Soriano A, Cornely OA, et al. Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial. Lancet. 2023 Jan 7;401(10370):49-59. 摘要

58. Falagas ME, Apostolou KE, Pappas VD. Attributable mortality of candidemia: a systematic review of matched cohort and case-control studies. Eur J Clin Microbiol Infect Dis. 2006 Jul;25(7):419-25. 摘要

59. Chow JK, Golan Y, Ruthazer R, et al. Risk factors for albicans and non-albicans candidemia in the intensive care unit. Crit Care Med. 2008 Jul;36(7):1993-8. 摘要

60. Playford EG, Marriott D, Nguyen Q, et al. Candidemia in nonneutropenic critically ill patients: risk factors for non-albicans Candida spp. Crit Care Med. 2008 Jul;36(7):2034-9. 摘要

61. Fraser VJ, Jones M, Dunkel J, et al. Candidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality. Clin Infect Dis. 1992 Sep;15(3):414-21. 摘要

62. Labelle AJ, Micek ST, Roubinian N, et al. Treatment-related risk factors for hospital mortality in Candida bloodstream infections. Crit Care Med. 2008 Nov;36(11):2967-72. 摘要

63. Khan FA, Slain D, Khakoo RA. Candida endophthalmitis: focus on current and future antifungal treatment options. Pharmacotherapy. 2007 Dec;27(12):1711-21. 摘要

64. Brod RD, Flynn HW Jnr, Miller D. Endogenous fungal endophthalmitis. In: Duane's opthalmology on CD-ROM, 2006 edition. Philadelphia: Lippincott Williams and Wilkins; 2006.

65. Clancy CJ, Nguyen MH. Finding the "missing 50%" of invasive candidiasis: how nonculture diagnostics will improve understanding of disease spectrum and transform patient care. Clin Infect Dis. 2013;56(9):1284-92.全文  摘要

66. Trevijano-Contador N, Torres-Cano A, Carballo-González C, et al. Global emergence of resistance to fluconazole and voriconazole in Candida parapsilosis in tertiary hospitals in Spain during the COVID-19 pandemic. Open Forum Infect Dis. 2022 Nov;9(11):ofac605.全文  摘要

67. Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016 Feb 15;62(4):e1-50.全文  摘要

68. Centers for Disease Control and Prevention. Candida auris. August 2018 [internet publication].全文